SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of layoffs in India and the Philippines, with termination notices citing a scaled-down business assignment, have sparked concern that Innodata may have lost or reduced a major client project. Traders are divided between that revenue-risk interpretation and the view that the cuts reflect efficiency or a shift to contract workers, with the uncertainty weighing on shares ahead of Q3 results.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

A recent rebound that held near breakout levels has prompted bullish swing-trade setups and call buying ahead of earnings. Traders are watching for follow-through, while some remain cautious about weak housing demand and interest-rate sensitivity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on ImmunityBios upcoming QUILT-2.005 Phase 3 topline readout of ANKTIVA plus BCG for first-line bladder cancer; the company has completed the database lock and says an sBLA filing is on track for Q4. Traders are largely optimistic about the potential label expansion, while also watching Q3 results and debating whether the clinical and commercial momentum will justify the bullish expectations.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is drawing attention after a sharp precious-metals selloff and a reported 52-week low, with traders citing Fed rate-hike expectations and possible forced liquidation as pressures. The community is split between calling gold a failed safe haven and viewing the decline as a buying opportunity, with some watching for support or a rebound.

World Liberty Financial (WLFI) is a cryptocurrency launched in 2025and operates on the Ethereum platform. World Liberty Financial has a current supply of 100,000,000,000 with 31,779,991,497 in circulation. The last known price of World Liberty Financial is 0.05007445 USD and is up 0.02 over the last 24 hours. It is currently trading on 491 active market(s) with $20,910,403.62 traded over the last 24 hours. More information can be found at https://www.worldlibertyfinancial.com/.

WorldFinancial

WLFI discussion centers on its prolonged weakness and concerns that Trump-family crypto monetization and potential token sales are weighing on sentiment. Bulls counter that a bank charter and USD1-related utility could support a rebound, though those catalysts are discussed largely as expectations, while skeptics see no near-term support.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is drawing attention after a sharp gain alongside elevated volatility and unusually heavy call activity. Traders are split between treating the move as a hedge against market risk and expecting the volatility spike to fade, citing the funds tendency to decay over time.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvanas post-earnings rally is the main focus: traders point to strong revenue and unit growth and the SECs decision not to pursue enforcement, while critics emphasize the EPS miss, margin pressure, reduced guidance, and insider share monetization. Bulls cite short-squeeze potential; bears question the valuation and durability of the gains.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Traders are framing disruptions to Qatari and other Middle Eastern LNG supply, including shipping risks around the Strait of Hormuz, as a potential tailwind for U.S. exporters and future contracting leverage at NextDecades Rio Grande project. Skeptics note that NEXT has not yet begun production and remains exposed to construction, financing, and execution risks ahead of planned first LNG output in 2027.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention after a steep selloff as investors await Q3 results to gauge whether Auvelitys Alzheimers-agitation launch is translating into paid prescriptions and whether commercial spending is delaying profitability. Some traders believe sampling and long-term-care channels understate demand, while others point to sluggish visible prescription growth, managements silence and cash-burn concerns.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs October delivery update is drawing attention, with traders highlighting a monthly record for overseas deliveries and stronger month-over-month vehicle sales while watching whether the company can meet its ambitious fourth-quarter delivery outlook. Reactions are mixed: some see expanding exports and volume as evidence of growth, while others question whether sales growth will translate into better margins and profitability amid the stocks prolonged decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corvuss presentation of early soquelitinib data in atopic dermatitis is the main focus: bullish traders view the results as promising, while critics say the event raised expectations without enough new detail and question the small data set and safety evidence. The stocks negative reaction has intensified that debate.

Corvus Pharma Q2 2026 Earnings Call Transcript

Corvus Pharma (NASDAQ:CRVS) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below.
This transcript is brought to you byread more...

Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting

Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting...

Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?

Key PointsDavid Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are presently covering the stock...

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8.3% - Here's Why

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 8.3% - What's Next...

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen raised shares of Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 10.2% - Here's Why

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 10.2% - What's Next...

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 9.5% - What's Next?

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 9.5% Higher - Here's What Happened...

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded at The Goldman Sachs Group

The Goldman Sachs Group raised shares of Corvus Pharmaceuticals to a "strong-buy" rating in a research note on Friday...

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside

Equity

Bearish Sentiment

In this photo illustration, the Corvus Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Goldman Sachs initiated coverage of Corvus with a ‘Buy’ rating and $40 price target, according to The Fly.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$10.03
Prev Close	$10.23
Open	$10.09
Dividend Yield	0.00%
50-Day Moving Average	$11.94
Beta	1.45
Avg. Volume	1.17M
PE Ratio	-16.24

52-Week High	$26.95
52-Week Low	$6.39
Market Capitalization	$843.73M
EPS (Annual)	-$0.5372
Price to Book	3.74
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRVS Fundamentals